LIVE — Auto-updated every 10 mins · Equity segment

Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—

Filed today

—

Companies tracked

NSE & BSE

Listed on

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.

Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split

Data sourced from BSE India corporate announcements. More categories will be added over time.

Jubilant Ingrevia Ltd

Jubilant Ingrevia acquires Remidex Pharma for Rs. 16.5 Cr cash

M&A ● No Immediate Change MEDIUM RISK

📅 Filed on BSE: 13 Mar 2026, 08:11 PM IST · BSE ID: 2192a781-6db7-424f-95f6-9d6bf0fff594

View Original BSE Filing (PDF)

🤖 AI Summary

Jubilant Ingrevia Limited has signed a Share Purchase Agreement to acquire 100% equity stake in Remidex Pharma Private Limited for Rs. 16.5 Cr in cash, subject to customary closing conditions. Remidex, incorporated June 15, 1981, manufactures multivitamin premixes and nutraceuticals from its Bangalore facility. The acquisition is expected to close within 30 days. Remidex recorded turnover of Rs. 24.27 Cr in FY 24-25, down from Rs. 31.15 Cr in FY 23-24. The deal is not a related-party transaction. Jubilant says this expands its human nutrition portfolio, building on its existing vitamins leadership.

🔢 Key Numbers — exact figures from BSE filing, not rounded

Acquisition price (cash consideration)

Rs. 16.5 Cr

Remidex turnover FY 24-25

Rs. 24.27 Cr

-22.2%

Remidex turnover FY 23-24

Rs. 31.15 Cr

Remidex turnover FY 22-23

Rs. 30.51 Cr

Stake acquired

100% Equity Shares

Expected deal closure timeline

30 days

👥 What This Means For Shareholders

✅

Action Required

No action required — informational filing only. Monitor for post-closing integration updates and impact on consolidated financial results.

👤

Who Is Affected

All existing shareholders are equally affected as this is a cash-funded acquisition with no equity dilution or share issuance. Future consolidated earnings will include Remidex's contribution post-closing.

🔍

Management Signal

Acquisition signals Jubilant's intent to diversify within nutrition — moving beyond vitamins into higher-value premix manufacturing to capture fuller value chain.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events

Deal closure announcement and confirmation of final purchase price within 30 days

Remidex integration roadmap and contribution to FY 25-26 consolidated results

Management commentary on premix segment margins and customer base synergies

MEDIUM RISK Target revenue declined 22% YoY; acquisition completion hinges on customary closing conditions. Integration execution and margin accretion timing unclear from filing.

💡 Investor Takeaway

Jubilant Ingrevia is acquiring Remidex Pharma's 100% stake for Rs. 16.5 Cr cash to enter premixes segment. Target is profitable but saw 22% revenue decline YoY to Rs. 24.27 Cr. Deal expected to close in 30 days with no related-party conflict.

⚖️ Strengths & Concerns

✅ Positives

Remidex is established player with 45-year track record since 1981 incorporation and WHO-GMP, FSSC, FSSAI certifications.
Deal structure is cash consideration only at Rs. 16.5 Cr with 30-day closure timeline and no regulatory approvals needed.

⚠️ Concerns

Remidex turnover declined 22.2% YoY to Rs. 24.27 Cr in FY 24-25 from Rs. 31.15 Cr prior year.
Acquisition price not disclosed relative to target's current or normalized earnings — no valuation basis provided.

📑 More from Jubilant Ingrevia Ltd

Jubilant Ingrevia: Sr. VP & Head HR Vinita Koul Resigns

MANAGEMENT · 27 Oct 2026

Jubilant Ingrevia Board Approves Q2 and Half-Year FY27 Financial Results

RESULTS · 27 Oct 2026

Jubilant Ingrevia: Tax Communication on Rs. 2.50 Final Dividend for FY26

DIVIDEND · 01 Aug 2026

Jubilant Ingrevia Submits Q1 FY27 Unaudited Standalone and Consolidated Financial Results

RESULTS · 24 Jul 2026

Jubilant Ingrevia Q1 FY27 Net Profit Rises 41% YoY to Rs. 106 Crore

RESULTS · 22 Jul 2026

Jubilant Ingrevia Q1 FY26 Consolidated Net Profit up 40.91% to Rs. 10582 Lakhs

RESULTS · 22 Jul 2026

All BSE filings we have analysed for Jubilant Ingrevia Ltd.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

Follow companies and get filings by email
Save any filing to read later
Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.